There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...

A new treatment strategy tested by UCLA researchers could offer new hope for men whose prostate cancer has returned after initial treatment. This approach could also help delay the need for hormone ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...

Although the Endocrine Society guidelines recommend TRT for men with testosterone levels ≤ 300 ng/dL in two morning samples, a primary concern is its potential to exacerbate prostate-related ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force (USPSTF). This independent panel of experts in preventive and primary care ...

ADT reduces testosterone, crucial for prostate cancer cell growth, but causes side effects impacting quality of life. Cardiovascular risks, insulin resistance, and bone density loss are significant ...

Focal therapy now helping in the fight against prostate cancer With focal therapy, doctors are now able to destroy cancer cells without damaging the surrounding nerves and tissue. In today’s ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

The average age of men who get diagnosed is 67.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.